ADCT
DEAD

Serial Number

90191738

Owner

ADC Therapeutics SA

Attorney

Tracy-Gene G. Durkin

Filing Date

Sep 18, 2020

Add to watchlist:

No watchlists yet
View on USPTO

ADCT Trademark

Serial Number: 90191738

ADCT is a trademark filed by ADC Therapeutics SA on September 18, 2020. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently no longer active.

Owner Contact Info

ADC Therapeutics SA (35 trademarks)

Route de la Corniche 3B
Epalinges 1066 , CH

Entity Type: 99

Trademark Details

Filing Date

September 18, 2020

Registration Date

Not Registered

Published for Opposition

May 24, 2022

Goods & Services

Pharmaceutical preparations and substances for use in oncology; pharmaceutical preparations for use in the prevention and treatment of cancer and tumors; pharmaceutical preparations for use in the prevention and treatment of infectious, oncological, inflammatory, immune, auto-immune, genetic, and rare diseases, disorders, and conditions; pharmaceutical preparations for human use, namely, pharmaceutical antibodies; pharmaceutical preparations for human use, namely, immunotherapies for the treatment of infectious, oncological, inflammatory, immune, auto-immune, genetic, and rare diseases, disorders, and conditions; pharmaceutical preparations, biological preparations, and gene therapy products in the nature of pharmaceutical and biological preparations for the treatment of infectious, oncological, inflammatory, immune, auto-immune, genetic, and rare diseases, disorders, and conditions; pharmaceutical preparations and substances for conditioning patients to receive therapies for the treatment of infectious, oncological, inflammatory, immune, auto-immune, genetic, and rare diseases, disorders, and conditions; diagnostic preparations for medical purposes; diagnostic biomarker reagents for medical purposes; diagnostic agents, preparations, and substances for medical purposes; reagents for medical use; diagnostic kits comprised of medical diagnostic reagents and assays to test tissue for use in the detection of infectious, oncological, inflammatory, immune, auto-immune, genetic, and rare diseases, disorders, and conditions; diagnostic kits comprised of medical diagnostic reagents and assays to test bodily fluids for use in the detection of infectious, oncological, inflammatory, immune, auto-immune, genetic, and rare diseases, disorders, and conditions; medical diagnostic assays for testing body fluids; medical diagnostic assays for testing body tissue; diagnostic kits comprised of medical diagnostic assays to test for cell expressions for use in identifying pharmaceutical preparations and therapies for treating medical diseases, disorders, and conditions in humans

Providing medical information; providing information in the fields of healthcare, therapeutic properties of pharmaceuticals, health, and wellness

Pharmaceutical drug development services; providing medical and scientific research information in the field of pharmaceuticals; Providing medical and scientific research information in the fields of clinical trials; scientific study and research in the field of pharmaceuticals for the treatment of cancer

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Oct 8, 2025 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Oct 8, 2025 ABN6
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jul 12, 2024 EXRA
SOU EXTENSION 4 GRANTED
Jul 12, 2024 EX4G
SOU EXTENSION 4 FILED
Jul 12, 2024 EXT4
SOU TEAS EXTENSION RECEIVED
Jul 12, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jan 18, 2024 EXRA
SOU EXTENSION 3 GRANTED
Jan 16, 2024 EX3G
SOU EXTENSION 3 FILED
Jan 16, 2024 EXT3
SOU TEAS EXTENSION RECEIVED
Jan 16, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jul 15, 2023 EXRA
SOU EXTENSION 2 GRANTED
Jul 13, 2023 EX2G
SOU EXTENSION 2 FILED
Jul 13, 2023 EXT2
SOU TEAS EXTENSION RECEIVED
Jul 13, 2023 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jan 20, 2023 EXRA
SOU EXTENSION 1 GRANTED
Jan 18, 2023 EX1G
SOU EXTENSION 1 FILED
Jan 18, 2023 EXT1
SOU TEAS EXTENSION RECEIVED
Jan 18, 2023 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Jul 19, 2022 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
May 24, 2022 NPUB
PUBLISHED FOR OPPOSITION
May 24, 2022 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
May 4, 2022 NONP
EXPARTE APPEAL TERMINATED
Apr 20, 2022 EXPT
APPROVED FOR PUB - PRINCIPAL REGISTER
Apr 20, 2022 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 12, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 12, 2022 CRFA
ASSIGNED TO LIE
Apr 11, 2022 ALIE
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Apr 6, 2022 ERFR
EX PARTE APPEAL-INSTITUTED
Apr 6, 2022 EXPI
JURISDICTION RESTORED TO EXAMINING ATTORNEY
Apr 6, 2022 JURT
EXPARTE APPEAL RECEIVED AT TTAB
Apr 6, 2022 EXAF
NOTIFICATION OF FINAL REFUSAL EMAILED
Oct 6, 2021 GNFN
FINAL REFUSAL E-MAILED
Oct 6, 2021 GNFR
FINAL REFUSAL WRITTEN
Oct 6, 2021 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Aug 3, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 3, 2021 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Aug 3, 2021 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Feb 3, 2021 GNRN
NON-FINAL ACTION E-MAILED
Feb 3, 2021 GNRT
NON-FINAL ACTION WRITTEN
Feb 3, 2021 CNRT
ASSIGNED TO EXAMINER
Feb 2, 2021 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Oct 28, 2020 NWOS
NEW APPLICATION ENTERED
Sep 22, 2020 NWAP